Aligos Therapeutics, Inc. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Aligos Therapeutics reported Q3 2026 results with cash/investments declining from $77.8M (Dec 2025) to $31.1M (Sept 2026)—a 60% burn in nine months. The company's Phase 2 B-SUPREME study of pevifoscorvir sodium enrolled 245 participants (131 HBeAg+, 114 HBeAg−) with topline data expected late Q3 2027. Cash runway extends only to Q1 2027. Net loss was $21.9M in Q3 2026 vs. $31.5M in Q3 2025; R&D expenses fell to $18.9M from $23.9M year-over-year. Partner Amoytop is funding ALG-170675 Phase 1 studies in China.
Why this rating
Severe cash burn (60% in 9 months) relative to $19.9M market cap is existential risk; Q1 2027 runway imminent. Offset by clinical progress and partnership, but funding urgency is critical.
Tradability signal
SHORT
conviction 47/100 · expected -1.69% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (271 in this cell) moved +1.85% in the called direction over 4 hrs; shrunk for sample size that's a +1.69% edge. Price is down 3.1% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $4.44 | +10 min · unknown $4.44 ▲ 0.00% | +30 min · unknown $4.44 ▲ 0.00% | +1 hr · unknown $4.49 ▲ 1.13% | +4 hrs · unknown $4.25 ▼ 4.19% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.